Israel - English - Ministry of Health

propharm ltd - oxybutynin hydrochloride - solution for intravesical - oxybutynin hydrochloride 1 mg / 1 ml - oxybutynin - vesoxx is indicated for the suppression of neurogenic detrusor overactivity (ndo) in children from 6 years of age and adults, who are managing bladder emptying by clean intermittent catheterization (cic), if they cannot be adequately managed by oral anticholinergic treatment due to lack of efficacy and/or intolerable side effects..

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

klosterfrau berlin gmbh, germany - tablet - 100 mg - garlic powder

Israel - English - Ministry of Health

propharm ltd - chlorhexidine digluconate; lidocaine hydrochloride - gel - chlorhexidine digluconate 0.5 mg / 1 g; lidocaine hydrochloride 20.0 mg / 1 g - lidocaine - local anesthesia prior exploration in urology (ureteroscopy, cystoscopy, urethral dilation, catheterization). for use during gynaecological investigation.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - lidocaine hydrochloride anhydrous (unii: ec2cnf7xfp) (lidocaine - unii:98pi200987) - glydo 2% jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of glydo 2% jelly. reproduction studies for lidocaine have been performed in both rats and rabbits. there was no evidence of harm to the fetus at subcutaneous doses of up to 50 mg/kg lidocaine (300 mg/m2 on a body surface area basis) in the rat model. in the rabbit model, there was no evidence of harm to the fetus at a dose of 5 mg/kg, s.c. (60 mg/m2 on a body surface area basis). treatment of rabbits with 25 mg/kg (300 mg/m2 ) produced evidence of maternal toxicity and evidence of delayed fetal development, including a non-significant decrease in fetal weight (7%) and an increase in minor skeletal anomalies (skull and sternebral de

Canada - English - Health Canada

mcm klosterfrau - balm oil; oil of orange; myristica oil; cinnamon oil - liquid - 27mg; 36mg; 4mg; 16mg - balm oil 27mg; oil of orange 36mg; myristica oil 4mg; cinnamon oil 16mg - herbs and natural products

Canada - English - Health Canada

novopharm limited - oxcarbazepine - tablet - 150mg - oxcarbazepine 150mg - miscellaneous anticonvulsants

Canada - English - Health Canada

novopharm limited - oxcarbazepine - tablet - 300mg - oxcarbazepine 300mg - miscellaneous anticonvulsants

Canada - English - Health Canada

novopharm limited - oxcarbazepine - tablet - 600mg - oxcarbazepine 600mg - miscellaneous anticonvulsants

Canada - English - Health Canada

novartis pharmaceuticals canada inc - oxcarbazepine - tablet - 150mg - oxcarbazepine 150mg - miscellaneous anticonvulsants

Canada - English - Health Canada

jubilant generics limited - oxcarbazepine - tablet - 150mg - oxcarbazepine 150mg - miscellaneous anticonvulsants